KAT6 is an emerging, clinically validated target in the treatment of ER+ breast cancer and other solid tumors
Selective degradation of KAT6A has potential for improved efficacy and tolerability.
About
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.